NAMSA’s full suite of global development services will help accelerate the commercialization of Terumo Aortic’s innovative aortic disease products.
TOLEDO, OHIO and SUNRISE, FLORIDA – BUSINESSWIRE—JUNE 21, 2023—NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and Terumo Aortic, a developer of aorta-focused medical devices, announced that they have entered into a strategic outsourcing partnership to assist with the acceleration and commercialization of Terumo Aortic’s innovative aortic disease products.
Terumo Aortic is a global medical device company dedicated to developing solutions for aortic disease. The company manufactures devices to treat thoracic and abdominal aneurysms, and acute and chronic dissections. Operating in over 100 countries globally, the organization is committed to providing treatment solutions for the entire aorta, while partnering with the clinical community to develop innovative solutions for patients.
“NAMSA could not be more pleased to announce the news of this strategic outsourcing partnership to facilitate growth for Terumo Aortic,” commented Christophe Berthoux, NAMSA CEO. “As part of this partnership, we have guaranteed Terumo Aortic immediate access to clinical experts for study starts and capacity, in addition to accessing our skilled and talented teams of cardiovascular-focused experts. We are honored to play a leading role in helping Terumo Aortic accelerate the introduction of life-enhancing devices,” Berthoux concluded.
The global MedTech industry is experiencing changing regulatory requirements and expanding clinical evidence demands, putting Sponsors at risk of longer development timelines, increased costs and lagged speed-to-market. NAMSA, with its strategic outsourcing solution and full suite of development services under one roof provides MedTech innovators the benefit of proactive planning and risk mitigation, preservation of capital and creation of stakeholder alignment. This ultimately leads to accelerated commercialization and products that are more readily available to patients that need them most.
Erik Pomp, Chief Executive Officer of Terumo Aortic commented, “We look forward to our strategic outsourcing partnership with NAMSA. NAMSA will play a vital role in our product development and this partnership will enable Terumo Aortic to accelerate the commercialization of our products. This will allow us to bring the latest technology and innovation to physicians and patients faster.”
NAMSA’s outsourcing collaboration with Terumo Aortic represents the CRO’s second such partnership; NAMSA announced its first outsourcing collaboration in September 2022.
Chris Rupp, MBA
Chris Rupp currently serves as Vice President of Global Marketing and Commercial Operations where he oversees teams across the organization’s portfolio of global development services. Chris has held a variety of other leadership roles within NAMSA where he was responsible for growing the CRO’s testing, clinical research and consulting solutions and helping Clients ultimately achieve successful product approval and commercialization. Over the course of his 20+ year career, he has also been involved in marketing and product development in the pharmaceutical, medical device and CRO industries.